Literature DB >> 1249208

Studies on the structural abnormality of fibrinogen Paris I.

M W Mosesson, D L Amrani, D Ménaché.   

Abstract

The structural properties of an inherited fibrinogen abnormality designated fibrinogen Paris I were investigated. Dodecyl sulfate gel electrophoresis of unreduced samples revealed no discernible differences in molecular weight from normal; this implied that in fibrinogen Paris I, the normal fibrinogen architecture of six covalently linked chains per molecule is preserved. Examination of dithiothreitol reduced samples before and after treatment with Reptilase or thrombin revealed that the Aalpha- and Bbeta-chains could release the A and B peptides, respectively. A mutant chain (mol wt 52,500, termed gammaParis I) which replaces a large proportion of gamma-chains (mol wt 49,400) was shown, like normal gamma-chains, to lack thrombin- and Reptilase-sensitive sites. The gamma-chains and alpha-chains of Paris I fibrin underwent Factor XIIIa-catalyzed cross-linking slowly; this behavior was not attributable to an intrinsic abnormality of these chains themselves but rather to the inhibitory effect of the mutant gammaParis I chains on this process. Results of DEAE-cellulose gradient elution chromatography of Paris I fibrinogen preparations revealed the presence of small amounts of normal fibrinogen molecules and also indicated that the gammaParis I chains possessed structural overlap with gamma-chains. Unlike gamma-chains however, the gammaParis I chains did not incorporate dansylcadaverine in the prescence of Factor XIIIa, nor, as previously reported, did they undergo cross-linking. The observations indicate that the amine acceptor site found in the COOH-terminal region of the gamma-chain is either not present on the gammaParis I chain or is unavailable for cross-linking. Further support for localization of the abnormality in the COOH-terminal region of the molecule was obtained from the observation that during plasmic hydrolysis of Paris I fibrinogen, at least one unique form of core Fragment D (DParis I) was evolved, whereas Fragment E did not differ from normal.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1249208      PMCID: PMC436714          DOI: 10.1172/JCI108337

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

1.  Crosslinking of human fibrin: Evidence for intermolecular crosslinking involving alpha-chains.

Authors:  R P. McDonagh; J McDonagh; M Blombäck; B Blombäck
Journal:  FEBS Lett       Date:  1971-04-12       Impact factor: 4.124

2.  High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physicochemical and immunological characterization.

Authors:  V J Marder; N R Shulman; W R Carroll
Journal:  J Biol Chem       Date:  1969-04-25       Impact factor: 5.157

3.  Human fibrinogen heterogeneities. I. Structural and related studies of plasma fibrinogens which are high solubility catabolic intermediates.

Authors:  M W Mosesson; J S Finlayson; R A Umfleet; D Galanakis
Journal:  J Biol Chem       Date:  1972-08-25       Impact factor: 5.157

4.  The effect of plasmin on the subunit structure of human fibrinogen.

Authors:  S V Pizzo; M L Schwartz; R L Hill; P A McKee
Journal:  J Biol Chem       Date:  1972-02-10       Impact factor: 5.157

5.  Titration of the acceptor cross-linking sites in fibrin.

Authors:  L Lorand; D Chenoweth; A Gray
Journal:  Ann N Y Acad Sci       Date:  1972-12-08       Impact factor: 5.691

6.  - cross-linking sites in human and bovine fibrin.

Authors:  R Chen; R F Doolittle
Journal:  Biochemistry       Date:  1971-11-23       Impact factor: 3.162

7.  The identification of isopeptide crosslinks in insoluble fibrin.

Authors:  S Matacić; A G Loewy
Journal:  Biochem Biophys Res Commun       Date:  1968-02-26       Impact factor: 3.575

8.  Polypeptide chain involved in the cross-linking of stabilized bovine fibrin.

Authors:  T Takagi; S Iwanaga
Journal:  Biochem Biophys Res Commun       Date:  1970-01-06       Impact factor: 3.575

9.  The cold-insoluble globulin of human plasma. I. Purification, primary characterization, and relationship to fibrinogen and other cold-insoluble fraction components.

Authors:  M W Mosesson; R A Umfleet
Journal:  J Biol Chem       Date:  1970-11-10       Impact factor: 5.157

10.  The preparation and properties of human fibrinogen of relatively high solubility.

Authors:  M W Mosesson; S Sherry
Journal:  Biochemistry       Date:  1966-09       Impact factor: 3.162

View more
  4 in total

1.  [Dysfibrinogenemia. A new case: dysfibrinogenemia Giessen III (author's transl)].

Authors:  F R Matthias; W H Krause; S Ganssert; K Mueller; H G Lasch
Journal:  Klin Wochenschr       Date:  1977-06-01

2.  The location of the carboxy-terminal region of gamma chains in fibrinogen and fibrin D domains.

Authors:  M W Mosesson; K R Siebenlist; D A Meh; J S Wall; J F Hainfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

3.  A gamma methionine-310 to threonine substitution and consequent N-glycosylation at gamma asparagine-308 identified in a congenital dysfibrinogenemia associated with posttraumatic bleeding, fibrinogen Asahi.

Authors:  K Yamazumi; K Shimura; S Terukina; N Takahashi; M Matsuda
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

4.  Human plasma fibrinogen heterogeneity: evidence for an extended carboxyl-terminal sequence in a normal gamma chain variant (gamma').

Authors:  C Wolfenstein-Todel; M W Mosesson
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.